Podcasts about wellcome trust sanger institute

Bernard Leong, Founder of Analyse Asia, and Jeremy Au talked about three main themes: 1. PhD to Serial Founder: Bernard talked about his initial career in academia, specializing in theoretical physics and obtaining his PhD in Astrophysics and Cosmology, before moving into machine learning at the Wellcome Trust Sanger Institute, home of the Human Genome Project. His entrepreneurial journey started with the co-founding of Chalkboard, a location-based advertising startup that faced strategic challenges and ended in a shutdown. He also co-founded SG Entrepreneurs, which successfully exited to Tech in Asia. He also shared his experiences heading digital transformation initiatives as a tech executive, such as his digital transformation leader at SingPost and pioneering Singapore's first-ever drone delivery. 2. Disrupting Extractive Enterprise Resource Planning (ERP) Systems: Bernard shared his vision for revolutionizing ERP systems to address the inefficiencies and high costs associated with traditional ERP software. He discussed the history of ERP systems and the challenges companies face, including high customization costs and the extractive nature of the consulting model associated with ERP implementation. Bernard aims to leverage generative AI technologies like ChatGPT and Microsoft CodePilot to create a next-generation open business operating system that is 10X more efficient, productive, and adaptable than current offerings. He discussed the reasons behind his focus on the medium segment of the small and medium enterprise market and counter-positioning strategy against existing ERP giants. 3. Startup vs. Family Career Decisions: Bernard compared the life of a serial entrepreneur to that of a football team manager, emphasizing the importance of taking each challenge as it comes. He discussed the practicalities of negotiating entrepreneurship with family responsibilities, highlighting the importance of financial planning, shared goals, and open communication with his wife who's also an entrepreneur. He also discussed what repeat founders do differently than first-time founders, ranging across distribution, mindset and adaptability. Jeremy and Bernard also touched on the "first love startup" problem, first-principles thinking, the people who bet against his success, and the future implications of AI in business.  Watch, listen or read the full insight at https://www.bravesea.com/blog/bernard-leong Nonton, dengar atau baca wawasan lengkapnya di https://www.bravesea.com/blog/bernard-leong-in 观看、收听或阅读全文，请访问 https://www.bravesea.com/blog/bernard-leong-cn Get transcripts, startup resources & community discussions at www.bravesea.com WhatsApp: https://chat.whatsapp.com/CeL3ywi7yOWFd8HTo6yzde TikTok: https://www.tiktok.com/@jeremyau Instagram: https://www.instagram.com/jeremyauz Twitter: https://twitter.com/jeremyau LinkedIn: https://www.linkedin.com/company/bravesea TikTok: https://www.tiktok.com/@jeremyau Instagram: https://www.instagram.com/jeremyauz Twitter: https://twitter.com/jeremyau LinkedIn: https://www.linkedin.com/company/bravesea English: Spotify | YouTube | Apple Podcasts Bahasa Indonesia: Spotify | YouTube | Apple Podcasts Chinese: Spotify | YouTube | Apple Podcasts Join the Singapore Growth & AI Summit with Sean Ellis! Use code seanbrave7 today.

Mark Pallen explains how exciting it was to be in microbial bioinformatics around the turn of the millennium, as we gained genomes for the first time from model organisms and fearsome pathogens. He recounts working with his hero David Relman on the genome sequencing of the strange slow-growing organism called Tropheryma whipplei in competition with a French team. Mark moved to Belfast in late 1999 collaborating with another Englishman working on the island of Ireland, Tim Foster in Dublin. Pallen describes the addictive exhilaration of using PSI-BLAST to find new sortases and sortase substrates across a range of new genomes—for him this was the bioinformatics equivalent of crack cocaine. He quotes the philosopher Alfred North Whitehead in saying that the goal of every scientist is to seek simplicity but distrust it. What Mark found was that in most organisms sortases were behaving quite differently from the rather simple scenario seen in Staphylococcus aureus. He made similar observations on the WXG100 proteins and type VII secretion, which he found in many new contexts quite different from the original context of ESAT-6 as an antigen in Mycobacterium tuberculosis. Mark makes clear that we still don't really fully understand the role of ESAT-6 twenty years on. The focus of Pallen's work then shifted to E. coli, where he described vestigial gene clusters for non-functional type III secretion systems in this model organism. He came to realize that E. coli K-12 was not handed to microbiologist by God as a model organism but was just another strain of E. coli and nothing special. Many of the earliest genomes to be sequenced came from worn-out lab strains. To counter this problem, Gordon Dougan at the Wellcome Trust Sanger Institute moved the focus to genome-sequencing freshly isolated minimally passaged isolates. With Brendan Wren, Pallen wrote a review article for nature, emphasizing the importance of adopting an eco-evo perspective when trying to interpret bacterial genomes. Around that time, Scott Beatson joined Pallen's group. Mark managed to persuade Scott to work on type III secretion in E. coli rather than Pseudomonas aeruginosa. The result was the discovery of dozens of new type III secretion effectors, tying together bioinformatics and lab work to culminate in a PNAS paper. References - https://microbinfie.github.io/2022/06/09/bioinformatics-in-the-noughties.html

In this episode, Itai and Martin talk to Sarah Teichman, Head of Cellular Genetics at the Wellcome Trust Sanger Institute and Director of Research in the Cavendish Laboratory in Cambridge, England. In her creative research, Sarah's thoughts constantly switch between her native languages – bioinformatics and genomics – and foreign languages, such as chemistry and physics. Sarah talks about storytelling vs. modeling when interpreting data, and discusses hard vs. soft hypotheses.Sarah is interested in global principles of protein interactions and gene expression, focusing her research on genomics and immunity. She is an EMBO member and a fellow of the Royal Society and the Academy of Medical Sciences. Sarah received numerous prizes, including the Lister Prize, Biochemical Society Colworth Medal, Royal Society Crick Lecture, and EMBO Gold Medal.For more information on Night Science, visit www.night-science.org .

Dr. Peter Campbell is head of cancer, aging, and somatic mutation, senior group leader, and joint head of the Cancer Genome Project at the Wellcome Trust Sanger Institute and is a practicing hematologist at Addenbrooke’s Hospital in Cambridge, in the United Kingdom. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. J. Nangalia and P.J. Campbell. Genome Sequencing during a Patient’s Journey through Cancer. N Engl J Med 2019;381:2145-2156.

In this episode of CUTalks, Shreya and Thomas talk to Patrick Short, co-founder and CEO of Sano Genetics, which aims to connect people with research in personalised medicine. Patrick has a background in bioinformatics research, having completed a PhD in mathematical genomics at the Wellcome Trust Sanger Institute. Listen to this episode for an insight into the personalised genomics industry, as well as the journey from PhD to founder and some important lessons learnt along the way.

This episode launches a new series within the show: crossover episodes! I’m teaming up with other genetics podcast to invite hosts of other shows to join me on DNA Today and sometimes I’ll be a guest on their show as well.Kicking off this new series is Dr. Patrick Short, the CEO of Sano Genetics. He is experienced in genomics research with a focus on large-scale genome sequencing projects and rare disorders. Previously he was at the Wellcome Trust Sanger Institute and the University of Cambridge in England. We explore current understandings of genetics of autism and Sano Genetics’s studies.On This Episode We Discuss:Sano Genetics’ for Patients, Consumers and ResearchersEligible Participants For Sano Genetics' StudiesUnderlying Autism and Mathematical AbilityCurrent Understanding of Autism GeneticsGenetic Testing for AutismUniversity of Cambridge’s Autism Research StudiesLargest Study of Psychological Sex Differences and Autistic TraitsThis episode is one part of our conversation, to hear the other half of our conversation check out their podcast, “The Genetics Podcast”. On that episode, Dr. Patrick Short interviews me about genetic counseling and cytogenetics.Stay tuned for the next new episode of DNA Today next week on Friday September 6th. New episodes are released on the first Friday of the month with some bonus episode thrown in there, like this one!See what else I am up to on Twitter, Instagram, Facebook and iTunes. Questions/inquiries can be sent to info@DNApodcast.com.This summer I was interviewed on a few podcasts including In EyeSight talking about impact social media’s impact on the rare diseases community and on Dr. Mara Karpel’s Your Golden Years sharing about genetic counseling and testing.

This week, we're presenting stories about times when science is just too much. Part 1: Fiona Calvert is a crier — but when she starts her PhD, she promises herself she’ll never cry in front of her colleagues. Part 2: After graduating with his PhD, Shane Hanlon struggles to find balance in his science career. Fiona Calvert is a third-year PhD student at the Wellcome Trust Sanger Institute where she focusses on the role of the immune system in Alzheimer’s disease. She uses stem cells to understand how genetic mutations can affect the functions of microglia, a vital immune cell in the brain. As well as being fascinated and constantly amazed by the biology of the brain, Fiona is also passionate about science communication and loves any opportunity to talk about the wonderful world of microglia!    Shane M Hanlon is a scientist turned communicator who masquerades as a storyteller. He got a PhD studying frogs and turtles, tried his hand in government, and is now a scientist who teaches scientists how to talk to non-scientists. Shane is also DC's oldest (but not bestest) Story Collider co-host & producer. He happily lives in Virginia (but still loves DC), tries to get outside with his partner and dog as much as possible, and is medicore at writing witty biographies. Find him @ecologyofshane. Learn more about your ad choices. Visit megaphone.fm/adchoices

Helena is interested in the functional effects of genetic variation in human induced pluripotent stem cells (iPSC). Her research combines computational and experimental methods in iPSC-based models to understand the cellular mechanisms that lead to rare human diseases. Helena is a human geneticist who leads a research group at the UCL Great Ormond Street Institute of Child Health. She is a MRC eMedLab career development fellow (www.emedlab.ac.uk) and holds an appointment also at the Wellcome Trust Sanger Institute. Helena received her PhD from the University of Helsinki, where she studied the genetic mechanisms underlying autism spectrum disorders. She then transitioned to functional genomics, using diverse next-generation sequencing -based assays to study how DNA sequence variation influences different levels of gene regulation in human cells, first at the University of Geneva, and then at the EMBL-EBI. She joined the Human Induced Pluripotent Stem Cells Initiative (www.hipsci.org) in 2014 and has since focused on the functional characterization of genetic variation in human iPS cells from hundreds of donors. The long-term goal of her research is to combine high-dimensional molecular data from iPSCs and iPSC-derived cell types with clinical data to comprehensively model the cellular mechanisms that lead to rare human diseases.

Francesco Iorio is a senior bioinformatician working with Open Targets: a public-private initiative involving teams at the Wellcome Trust Sanger Institute, the EMBL – European Bioinformatics Institute, GlaxoSmithKline and Biogen, with the mission of exploiting Big Data for systematically identifying new therapeutic targets. Previously he was an ESPOD fellow in joint post-doctoral program between the European Bioinformatics Institute and the Wellcome Trust Sanger Institute under the guidance of Julio Saez-Rodriguez and Mathew Garnett. If you have any comments or questions email us on stemcellsatlunch@kcl.ac.uk

Adam Rutherford goes the pathology archive of Great Ormond Street Hospital in London to hear how tumour samples from child patients about one hundred years ago may improve the diagnosis and treatment of very rare cancers in children today. He meets cancer geneticist Sam Behjati of the Wellcome Trust Sanger Institute and Great Ormond Street pathologist Neil Sebire in the hospital's basement archive. Africa now has its first radio telescope outside South Africa. It is located in Ghana near the capital Accra. The telescope is in fact a defunct telecoms satellite dish which was spotted on Google Earth images and then re-purposed for cutting edge astrophysics. It is hoped the dish will be the founding instrument of a pan African network of radio telescopes scrutinising exotic celestial objects in the skies above the continent. South African science journalist Sarah Wilds tells the story of how the Ghanaian dish was found and converted. Nano-engineers in California have created a device 100 times thinner than a human hair which they have used to measure the turbulence created by swimming microbes and record the sounds of heart cells contracting. Don Sirbuly is the professor of nano-engineering at the University of California San Diego who led the team. A spectacular new whale fossil unearthed Peru is the oldest known member of the evolutionary branch which gave rise to the giant filter-feeding baleen whales of today. The 36 million year old fossil provides evidence for how ancestral whales transitioned from capturing prey with their teeth to filter-feeding with baleen fibres. They may gone through a period of sucking prey from the sea bed.

Our ability to extract DNA from old bones is improving, giving us a much clearer picture of who our ancestors were, and what they did. Two new papers out this week in Nature Communications are filling in some gaps in our knowledge of the history of Britain. One of the pieces of research - led by Professor Dan Bradley from Trinity College Dublin - examines DNA from individuals who died in northeast England at the beginning of the first millennium of the current era. The other paper analyses the genomes of East Anglian people who lived at a similar and slightly later time, and the lead author is Dr Stephan Schiffels. He worked at the Wellcome Trust Sanger Institute near Cambridge at the time of this research, and is now based at the Max Planck Institute for the Science of Human History. Professor Mark Thomas from University College London is a co-author on Dan Bradley's paper and joins Adam Rutherford to discuss this research in the context of its rapidly changing field. Concorde flew its first commercial flight on the 21st January 1976. To mark its 40th birthday, Concorde engineer Christopher Mitchell and Concorde pilot David Rowland talk about the extraordinary aeroplane's scientific and engineering legacy. What looked like an innocent rocky outcrop in the Argentinian desert turned out to be something completely different: An eight foot long femur, belonging to the world's largest dinosaur. Ben Garrod is one of the team who has put together this as yet unnamed behemoth. He talks us through the extraordinary discovery and journey to investigate a new species - and it's only just beginning. The work has been documented as part of the TV programme 'Attenborough & the Giant Dinosaur', due to air at 6.30pm this Sunday 24th Jan on BBC One. Finally, today's headlines indicate that we might have been missing something fairly substantial in our very own solar system: A new ninth planet. However, as BBC Science Correspondent Jonathan Amos tells us, this isn't yet confirmed. With Dr Ellen Stofan, NASA Chief Scientist. Producer: Jen Whyntie.

Dr. Daniel MacArthur is Assistant Professor at Harvard Medical School and Massachusetts General Hospital and an Associate Member of the Broad Institute of Harvard and MIT. Daniel received his PhD in Human Genetics from the University of Sydney and served as a Postdoctoral Scientist at Children's Hospital at Westmead. Daniel worked as a Research Fellow at Wellcome Trust Sanger Institute before accepting his current appointments. In addition to his superb research, Daniel has written many blog articles for both Wired Science and ScienceBlogs.com. Daniel is here with us today to tell us all about his journey through life and science.

Recent years have seen huge developments in the field of medical genomics and indeed their adoption into mainstream healthcare. How has our understanding of the topic evolved and what further progress is envisioned?  What are the ethical, social and legal implications that such developments entail? For patients, policy makers, law enforcement,  the insurance industry and society as a whole. Recorded live at Editorial Intelligence’s annual ideas festival Names Not Numbers. Co-curated and held in association with the Wellcome Trust.   Chair: Mark Henderson, Head of Communications, The Wellcome Trust Panel: Baroness Helena Kennedy QC, Barrister and Broadcaster, former Chair of the British Council and Chair of the Human Genetics Commission. Anna Middleton, Ethics Researcher, The Wellcome Trust Sanger Institute Professor Sir Mike Stratton, Director, The Wellcome Trust Sanger Institute

A decade ago, the Human Genome Project revealed that only 1% of our DNA codes for the proteins that make our bodies. The rest of the genome, it was said, was junk, in other words with no function. But in September another massive international project, called ENCODE, announced that the junk DNA is useful after all. Adam Rutherford reports on the significance of this major discovery. He visits the Wellcome Trust Sanger Institute outside Cambridge where the vast amount of data about our genome is produced and analysed. And he finds out how this new information is beginning to give insights into the origin and treatment of diseases, such as cancer. Adam also discovers that the study of genomes has changed dramatically since he finished his PhD: it's now all done in machines and not at the lab bench.

A decade ago, the Human Genome Project revealed that only 1% of our DNA codes for the proteins that make our bodies. The rest of the genome, it was said, was junk, in other words with no function. But in September another massive international project, called ENCODE, announced that the junk DNA is useful after all. Adam Rutherford reports on the significance of this major discovery. He visits the Wellcome Trust Sanger Institute outside Cambridge where the vast amount of data about our genome is produced and analysed. And he finds out how this new information is beginning to give insights into the origin and treatment of diseases, such as cancer. Adam also discovers that the study of genomes has changed dramatically since he finished his PhD: it's now all done in machines and not at the lab bench.

Adam Smith takes a tour of the Wellcome Trust Sanger Institute, Europe's leading genetics institute, home to the team that made the largest single contribution to the sequencing of the human genome.

Science Chat talks to Dr Don Powell of the Wellcome Trust Sanger Institute about a talk that he presented at ESOF 2010 in Turin